We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Alcoa
AA
$13.4B
| $9.91M | 0.01% |
190,000
+10,000
| +6% | +$670K |
|
727
Albertsons Companies
ACI
$5.75B
| $9.87M | 0.01% |
729,835
+128,198
| +21% | +$2.05M |
|
728
Atara Biotherapeutics
ATRA
$99.5M
| $9.76M | 0.01% |
850,000
+150,000
| +21% | +$1.2M |
|
|
FLG
729
Flagstar Bank National Association
FLG
$5.5B
| $9.67M | 0.01% |
646,969
-198,458
| -23% | -$2.81M |
|
730
SM Energy
SM
$9.03B
| $9.66M | 0.01% |
370,000
+70,000
| +23% | +$2.1M |
|
731
Axcelis
ACLS
$3.57B
| $9.62M | 0.01% |
50,777
+43,277
| +577% | +$6.42M |
|
732
Akamai
AKAM
$15.9B
| $9.41M | 0.01% |
79,600
+26,200
| +49% | +$3.26M |
|
733
Palisade Bio
PALI
$357M
| $9.4M | 0.01% |
4,500,000
| – | – |
|
734
Velocity Financial
VEL
$715M
| $9.33M | 0.01% |
505,505
+22,790
| +5% | +$415K |
|
735
Century Therapeutics
IPSC
$368M
| $9.28M | 0.01% |
3,789,538
| – | – |
|
736
The Mosaic Company
MOS
$8.33B
| $9.18M | 0.01% |
+433,320
| New | +$10M |
|
737
NorthWestern Energy
NWE
$4.34B
| $9.09M | 0.01% |
126,975
-149,029
| -54% | -$10.6M |
|
|
WHK
738
WhiteHawk Minerals Corp
WHK
$676M
| $9.09M | 0.01% |
+326,666
| New | +$8.86M |
|
|
SIND
739
Sinda Ltd
SIND
$2.64B
| $9M | 0.01% |
+750,000
| New | +$9M |
|
740
Pegasystems
PEGA
$5.76B
| $8.99M | 0.01% |
300,000
-200,000
| -40% | -$7.16M |
|
|
WENC
741
West Enclave Merger Corp
WENC
| $8.93M | 0.01% |
+900,000
| New | +$8.92M |
|
742
Best Buy
BBY
$18.5B
| $8.92M | 0.01% |
117,600
-258,300
| -69% | -$17.2M |
|
|
FTHA
743
Forefront Tech Holdings Acquisition Corp
FTHA
$137M
| $8.91M | 0.01% |
+900,000
| New | +$8.92M |
|
744
Labcorp
LH
$26B
| $8.85M | 0.01% |
31,600
-74,400
| -70% | -$19.6M |
|
745
Public Service Enterprise Group
PEG
$36.2B
| $8.61M | 0.01% |
+106,084
| New | +$8.47M |
|
746
Builders FirstSource
BLDR
$6.61B
| $8.58M | 0.01% |
95,900
+30,200
| +46% | +$2.41M |
|
747
CAMP4 Therapeutics
CAMP
$272M
| $8.57M | 0.01% |
1,960,784
| – | – |
|
748
Otis Worldwide
OTIS
$26.4B
| $8.41M | 0.01% |
117,415
+23,800
| +25% | +$1.78M |
|
749
Zimmer Biomet
ZBH
$18B
| $8.35M | 0.01% |
96,942
+40,048
| +70% | +$3.51M |
|
750
Weyerhaeuser
WY
$16.3B
| $8.2M | 0.01% |
+342,600
| New | +$8.32M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.